CN1480466A - 一类溶栓抗凝双功能融合蛋白及应用 - Google Patents
一类溶栓抗凝双功能融合蛋白及应用 Download PDFInfo
- Publication number
- CN1480466A CN1480466A CNA021290865A CN02129086A CN1480466A CN 1480466 A CN1480466 A CN 1480466A CN A021290865 A CNA021290865 A CN A021290865A CN 02129086 A CN02129086 A CN 02129086A CN 1480466 A CN1480466 A CN 1480466A
- Authority
- CN
- China
- Prior art keywords
- fusion rotein
- fxa
- hirudin
- activity
- recognition sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 17
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 12
- 230000002537 thrombolytic effect Effects 0.000 title claims description 10
- 230000010100 anticoagulation Effects 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
- 229940006607 hirudin Drugs 0.000 claims abstract description 31
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 13
- 102000013566 Plasminogen Human genes 0.000 claims abstract description 10
- 108010051456 Plasminogen Proteins 0.000 claims abstract description 10
- 230000004927 fusion Effects 0.000 claims description 49
- 108010074860 Factor Xa Proteins 0.000 claims description 27
- 150000001413 amino acids Chemical group 0.000 claims description 25
- 101710145796 Staphylokinase Proteins 0.000 claims description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 23
- 108090000190 Thrombin Proteins 0.000 claims description 16
- 229960004072 thrombin Drugs 0.000 claims description 16
- 235000001014 amino acid Nutrition 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 230000004913 activation Effects 0.000 claims description 9
- 229940012957 plasmin Drugs 0.000 claims description 7
- 239000004019 antithrombin Substances 0.000 claims description 6
- 239000003146 anticoagulant agent Substances 0.000 claims description 5
- 229940127219 anticoagulant drug Drugs 0.000 claims description 5
- 230000023555 blood coagulation Effects 0.000 claims description 5
- 210000004899 c-terminal region Anatomy 0.000 claims description 5
- 235000018102 proteins Nutrition 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 3
- 108010001014 Plasminogen Activators Proteins 0.000 claims description 3
- 102000001938 Plasminogen Activators Human genes 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 229940127126 plasminogen activator Drugs 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 230000017531 blood circulation Effects 0.000 claims description 2
- 230000015271 coagulation Effects 0.000 claims description 2
- 238000005345 coagulation Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 102000009123 Fibrin Human genes 0.000 claims 2
- 108010073385 Fibrin Proteins 0.000 claims 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 2
- 230000002429 anti-coagulating effect Effects 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 229950003499 fibrin Drugs 0.000 claims 2
- 241000235648 Pichia Species 0.000 claims 1
- 238000005336 cracking Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 108010007267 Hirudins Proteins 0.000 abstract description 11
- 102000007625 Hirudins Human genes 0.000 abstract description 4
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 abstract description 4
- 102000037865 fusion proteins Human genes 0.000 abstract description 3
- 108020001507 fusion proteins Proteins 0.000 abstract description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 2
- 102000009064 Antithrombin Proteins Human genes 0.000 abstract 1
- 108010049298 Antithrombin Proteins Proteins 0.000 abstract 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 abstract 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 abstract 1
- 102000030595 Glucokinase Human genes 0.000 abstract 1
- 108010021582 Glucokinase Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000003114 blood coagulation factor Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 108091008146 restriction endonucleases Proteins 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 5
- 230000029087 digestion Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010023197 Streptokinase Proteins 0.000 description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 229960005202 streptokinase Drugs 0.000 description 3
- 101150010939 tpa gene Proteins 0.000 description 3
- 229960005356 urokinase Drugs 0.000 description 3
- 101150076271 SAK gene Proteins 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 102100033571 Tissue-type plasminogen activator Human genes 0.000 description 2
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000007500 overflow downdraw method Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021290865A CN1480466A (zh) | 2002-09-03 | 2002-09-03 | 一类溶栓抗凝双功能融合蛋白及应用 |
| AT03793572T ATE376001T1 (de) | 2002-09-03 | 2003-09-03 | Kondensiertes protein, das sowohl thrombolytisch als auch gerinnungshemmend wirkt, und dessen verwendung |
| US10/526,682 US8212003B2 (en) | 2002-09-03 | 2003-09-03 | Bifunctional fusion protein with thrombolytic and anticoagulant activities and uses thereof |
| PCT/CN2003/000743 WO2004022598A1 (fr) | 2002-09-03 | 2003-09-03 | Proteine hybride assurant les fonctions d'hemolyse et d'anticoagulation |
| CNB038207729A CN1301268C (zh) | 2002-09-03 | 2003-09-03 | 溶栓和抗凝双功能融合蛋白及应用 |
| EP03793572A EP1541589B1 (en) | 2002-09-03 | 2003-09-03 | Fused protein with the function of both thrombolysis and anticoagulation and the use of it |
| AU2003261606A AU2003261606A1 (en) | 2002-09-03 | 2003-09-03 | Fused protein with the function of both hemolysis and anticoagulation and the use of it |
| JP2004533177A JP2006516113A (ja) | 2002-09-03 | 2003-09-03 | 血栓溶解および抗凝固両方の機能を有する融合タンパク質、ならびにその使用 |
| DE60316967T DE60316967T2 (de) | 2002-09-03 | 2003-09-03 | Kondensiertes protein, das sowohl thrombolytisch als auch gerinnungshemmend wirkt, und dessen verwendung |
| JP2010106629A JP2010184930A (ja) | 2002-09-03 | 2010-05-06 | 血栓溶解および抗凝固両方の機能を有する融合タンパク質、ならびにその使用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021290865A CN1480466A (zh) | 2002-09-03 | 2002-09-03 | 一类溶栓抗凝双功能融合蛋白及应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1480466A true CN1480466A (zh) | 2004-03-10 |
Family
ID=31954566
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA021290865A Pending CN1480466A (zh) | 2002-09-03 | 2002-09-03 | 一类溶栓抗凝双功能融合蛋白及应用 |
| CNB038207729A Expired - Fee Related CN1301268C (zh) | 2002-09-03 | 2003-09-03 | 溶栓和抗凝双功能融合蛋白及应用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB038207729A Expired - Fee Related CN1301268C (zh) | 2002-09-03 | 2003-09-03 | 溶栓和抗凝双功能融合蛋白及应用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8212003B2 (https=) |
| EP (1) | EP1541589B1 (https=) |
| JP (2) | JP2006516113A (https=) |
| CN (2) | CN1480466A (https=) |
| AT (1) | ATE376001T1 (https=) |
| AU (1) | AU2003261606A1 (https=) |
| DE (1) | DE60316967T2 (https=) |
| WO (1) | WO2004022598A1 (https=) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100519585C (zh) * | 2007-02-06 | 2009-07-29 | 中国人民解放军军事医学科学院基础医学研究所 | P11与sak的融合蛋白及其制备方法和用途 |
| CN102180973A (zh) * | 2011-03-18 | 2011-09-14 | 重庆大学 | 靶向多功能防栓融合蛋白及其制备方法和应用 |
| CN102533702A (zh) * | 2007-09-28 | 2012-07-04 | 普托拉制药有限公司 | 用于因子xa抑制剂的解毒剂和其使用方法 |
| CN106366200A (zh) * | 2015-07-23 | 2017-02-01 | 武汉光谷人福生物医药有限公司 | 制备重组葡激酶-水蛭素融合蛋白的方法 |
| CN113150168A (zh) * | 2021-01-29 | 2021-07-23 | 武汉真福医药股份有限公司 | 一种qk纤溶酶基因-水蛭素融合蛋白的制备方法及应用 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1896108B (zh) * | 2005-06-01 | 2012-01-04 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 特异性抗凝血物质的制备及其应用 |
| CN102443065A (zh) * | 2005-06-01 | 2012-05-09 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 特异性抗凝血物质的制备及其应用 |
| EP1816201A1 (en) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| JP2009536821A (ja) * | 2006-05-12 | 2009-10-22 | バハラ バイオテック インターナショナル リミテッド | 新規血栓溶解分子及びその製造法 |
| ATE533789T1 (de) | 2006-12-15 | 2011-12-15 | Inst Radiation Med Amms Pla | Herstellung von mit geringen blutungen assoziiertem gerinnungshemmendem fusionsprotein und dessen verwendung |
| EP2526962B1 (en) * | 2007-02-12 | 2019-08-14 | CSL Behring GmbH | Therapeutic application of Kazal-type serine protease inhibitors |
| DE102009010611A1 (de) * | 2009-02-25 | 2010-08-26 | Siemens Aktiengesellschaft | Vorrichtung und Verfahren zur Steuerung einer mit mehreren Brennern ausgestatteten Turbine für flüssige oder gasförmige Brennstoffe |
| US9150844B2 (en) * | 2010-08-05 | 2015-10-06 | Neeraj Maheshwari | Protein fusion constructs possessing thrombolytic and anticoagulant properties |
| WO2014037373A1 (en) * | 2012-09-07 | 2014-03-13 | Sanofi | Fusion proteins for treating a metabolic syndrome |
| JP7028904B2 (ja) * | 2019-03-21 | 2022-03-02 | アカデミア シニカ | 合成ペプチド、それを備える薬学的組成物及び血栓塞栓症関連疾患の治療におけるその使用 |
| KR102789819B1 (ko) * | 2021-10-21 | 2025-03-31 | 중앙대학교 산학협력단 | 트롬빈 검출용 신규한 펩타이드 및 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5298599A (en) * | 1988-12-30 | 1994-03-29 | Oklahoma Medical Research Foundation | Expression and purification of recombinant soluble tissue factor |
| GB8927722D0 (en) * | 1989-12-07 | 1990-02-07 | British Bio Technology | Proteins and nucleic acids |
| US5759542A (en) * | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US6015787A (en) * | 1997-11-04 | 2000-01-18 | New England Medical Center Hospitals, Inc. | Cell-permeable protein inhibitors of calpain |
| US6423680B1 (en) * | 1998-10-30 | 2002-07-23 | Hsc Research And Development Limited Partnership | Inhibitor of platelet activating factor |
| CN1188522C (zh) * | 2001-07-20 | 2005-02-09 | 健力福生化技术（上海）有限公司 | 一种血栓靶向性溶栓蛋白表达质粒及其构建 |
| CN1181099C (zh) * | 2002-07-23 | 2004-12-22 | 中国人民解放军第二军医大学 | 兼抗凝溶栓双重功能的血栓靶向融合蛋白mA5UKB |
-
2002
- 2002-09-03 CN CNA021290865A patent/CN1480466A/zh active Pending
-
2003
- 2003-09-03 CN CNB038207729A patent/CN1301268C/zh not_active Expired - Fee Related
- 2003-09-03 JP JP2004533177A patent/JP2006516113A/ja active Pending
- 2003-09-03 AT AT03793572T patent/ATE376001T1/de not_active IP Right Cessation
- 2003-09-03 AU AU2003261606A patent/AU2003261606A1/en not_active Abandoned
- 2003-09-03 EP EP03793572A patent/EP1541589B1/en not_active Expired - Lifetime
- 2003-09-03 WO PCT/CN2003/000743 patent/WO2004022598A1/zh not_active Ceased
- 2003-09-03 US US10/526,682 patent/US8212003B2/en not_active Expired - Fee Related
- 2003-09-03 DE DE60316967T patent/DE60316967T2/de not_active Expired - Lifetime
-
2010
- 2010-05-06 JP JP2010106629A patent/JP2010184930A/ja active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100519585C (zh) * | 2007-02-06 | 2009-07-29 | 中国人民解放军军事医学科学院基础医学研究所 | P11与sak的融合蛋白及其制备方法和用途 |
| CN102533702A (zh) * | 2007-09-28 | 2012-07-04 | 普托拉制药有限公司 | 用于因子xa抑制剂的解毒剂和其使用方法 |
| CN102559644B (zh) * | 2007-09-28 | 2015-03-25 | 普托拉制药有限公司 | 用于因子xa抑制剂的解毒剂和其使用方法 |
| CN102180973A (zh) * | 2011-03-18 | 2011-09-14 | 重庆大学 | 靶向多功能防栓融合蛋白及其制备方法和应用 |
| CN106366200A (zh) * | 2015-07-23 | 2017-02-01 | 武汉光谷人福生物医药有限公司 | 制备重组葡激酶-水蛭素融合蛋白的方法 |
| CN113150168A (zh) * | 2021-01-29 | 2021-07-23 | 武汉真福医药股份有限公司 | 一种qk纤溶酶基因-水蛭素融合蛋白的制备方法及应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006516113A (ja) | 2006-06-22 |
| JP2010184930A (ja) | 2010-08-26 |
| AU2003261606A1 (en) | 2004-03-29 |
| CN1301268C (zh) | 2007-02-21 |
| EP1541589B1 (en) | 2007-10-17 |
| EP1541589A1 (en) | 2005-06-15 |
| WO2004022598A1 (fr) | 2004-03-18 |
| CN1678636A (zh) | 2005-10-05 |
| DE60316967T2 (de) | 2008-05-08 |
| DE60316967D1 (de) | 2007-11-29 |
| US8212003B2 (en) | 2012-07-03 |
| US20060127389A1 (en) | 2006-06-15 |
| EP1541589A4 (en) | 2005-11-16 |
| ATE376001T1 (de) | 2007-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1480466A (zh) | 一类溶栓抗凝双功能融合蛋白及应用 | |
| Blombäck et al. | A two-step fibrinogen–fibrin transition in blood coagulation | |
| Cheng et al. | Identification and inhibitory activity against α-thrombin of a novel anticoagulant peptide derived from oyster (Crassostrea gigas) protein | |
| Nakajima et al. | Chemical modification of earthworm fibrinolytic enzyme with human serum albumin fragment and characterization of the protease as a therapeutic enzyme | |
| CN101514231B (zh) | 靶向性抗血栓形成的融合蛋白及其制备方法和应用 | |
| JP2005525798A (ja) | 微生物内での組み換えタンパク質の生産方法 | |
| CN113416724B (zh) | 一种组织型纤溶酶原激活剂的重组蛋白及其应用 | |
| JP2006516113A5 (https=) | ||
| Arni et al. | Structure of the non-covalent complex of prothrombin kringle 2 with PPACK-thrombin | |
| EP2600891B1 (en) | Protein fusion constructs possessing thrombolytic and anticoagulant properties | |
| CN101705240B (zh) | 巴曲酶基因的合成及其表达产物的制备方法 | |
| US20060281147A1 (en) | Thrombin-like recombinant baxtroxobin expressed by pichia sp.and production method thereof | |
| CN101284877A (zh) | 重组靶向抗凝血酶活性和抗血小板聚集的融合蛋白及制备方法 | |
| US8017750B2 (en) | Haemocoagulase | |
| CN101812436B (zh) | 一种尖吻蝮蛇蛇毒类凝血酶及其制备方法和应用 | |
| Zhao et al. | An overview of the fibrinolytic enzyme from earthworm | |
| JPH0965879A (ja) | 新規血栓溶解酵素とその製造方法 | |
| Hernández et al. | Streptokinase: about of a thrombolytic patented in Cuba | |
| CN102258483B (zh) | 一种抗血栓的重组巴曲酶冻干制剂 | |
| EP0487660B1 (en) | Treatment of thrombotic events | |
| KR100796360B1 (ko) | 효모로부터 발현된 재조합 트롬빈 유사 효소 배트록소빈 및그 생산방법 | |
| CN100424172C (zh) | 一种定向突变的基因工程巴曲酶及用途 | |
| CN100355783C (zh) | 一种抗凝蛋白及其编码基因与它的高效表达方法 | |
| EP2186826B1 (en) | Chimeric hirudin proteins | |
| Zhao-Fa et al. | Recombinant batroxobin expressed highly in Pichia pastoris |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |